Table 2.

Associations between clinical variables and the primary outcome femoral neck BMD (g/cm²) as determined by univariable linear regression.

	β	95% CI	p-value
Low disease activity^a,b	0.050	−0.003 to 0.104	0.066
Age at time of DXA (years)	−0.006	−0.008 to −0.004	<0.0001
Female	−0.045	−0.117 to 0.026	0.212
Race/Ethnicity
Hispanic/Latino	−0.053	−0.116 to 0.010	0.097
Asian	−0.099	−0.164 to −0.033	0.003
Other	ref	--	--
RA disease duration	−0.002	−0.005 to 0.002	0.321
BMI	0.009	0.006 to 0.013	<0.0001
csDMARD use^c	0.018	−0.081 to 0.116	0.724
bDMARD use^c	0.073	0.011 to 0.135	0.022
Prednisone (mg/day)^b	0.004	−0.003 to 0.010	0.250
RF positive	−0.001	−0.073 to 0.072	0.989
ACPA positive	−0.024	−0.087 to 0.040	0.466
OP medication use (ever)	−0.047	−0.094 to −0.001	0.049
Number of visits	0.001	−0.001 to 0.002	0.379

-DAS28ESR: Disease activity score 28-joints with erythrocyte sedimentation rate; DXA: dual x-ray absorptiometry; RA: rheumatoid arthritis; BMI: body mass index; csDMARD: conventional synthetic disease modifying antirheumatic drug; bDMARD: biologic disease modifying anti-rheumatic drug; RF: rheumatoid factor; ACPA: anti-cyclic citrullinated peptide; OP: osteoporosis.

-p-value:

<0.1,

^**

<0.05,

^***

<0.001.

^a-

Low DAS28ESR ≤3.2 vs. moderate/high DAS28ESR >3.2.

^b-

Cumulative values calculated using trapezoidal area under the curve/observation time.

^c-

Calculated as proportion (%) of visits where participant was taking bDMARDs or csDMARDs.